Showed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy.

显示15例经过严重预处理的晚期实体瘤患者的HCW9218临床安全性和肿瘤反应终点导致卵巢癌患者超过其他适应症，其中66%稳定疾病MIRAMAR，Fla。，2023年11月8日（GLOBE NEWSWIRE）-HCW Biologics Inc.（该公司或“HCW Biologics”）（纳斯达克股票代码：HCWB），一家临床阶段的生物制药公司专注于发现和开发新的免疫疗法，通过破坏炎症与年龄相关疾病之间的联系来延长健康范围，明尼苏达大学赞助的一项正在进行的第一阶段临床试验的初步人体数据读数结果公布了评估HCW生物制剂的主要候选药物HCW9218，在实体瘤患者中至少有两个以前的治疗方案失败。

Data from this study was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota who serves as a Principal Investigator of this trial.

本研究的数据由Melissa A.Geller，M.S.，明尼苏达大学妇产科和妇女健康系妇科肿瘤学教授兼分部主任在癌症免疫治疗学会（“SITC”）第38届年会上提出，他是该试验的主要研究者。

This clinical readout was based on 15 patients who were enrolled in the study as of October 16, 2023, all of whom were patients whose disease had previously progressed after multiple lines of standard-of-care therapy. The trial is now in its final expanded dose level, and the Company expects it to be completed in the fourth quarter of 2023.

该临床读数基于截至2023年10月16日参加该研究的15名患者，所有患者均为先前在多种标准护理疗法后疾病进展的患者。该试验目前处于最终扩大剂量水平，公司预计将于2023年第四季度完成。

There has been one dose-limiting toxicity experience in this study, but it did not trigger stopping rules. Highlights of data presented at SITC include: HCW9218 was administered subcutaneously once every three weeks for up to six cycles at dose levels 0.25 mg/kg (DL1), 0.5 mg/kg (DL2), 0.8 mg/kg (DL3) .

在这项研究中有一个剂量限制性毒性经验，但它没有触发停止规则。SITC提供的数据重点包括：HCW9218每三周皮下注射一次，最多六个周期，剂量水平为0.25 mg/kg（DL1），0.5 mg/kg（DL2），0.8 mg/kg（DL3）。